Four IF protocols — TRE (16/8), alternate-day fasting, 5:2, and OMAD — converge on a shared molecular architecture: AMPK activation suppresses mTOR while triggering ULK1-mediated autophagy initiation, with downstream engagement of SIRT1/3, PGC-1α, and transcription factor EB (TFEB) to coordinate mitochondrial biogenesis, oxidative stress defense, and lysosomal clearance. These cascades translate clinically into improved glycemic control, favorable lipid remodeling, and reduced inflammatory tone relevant to cardiometabolic and neurodegenerative risk.
The value here isn't novelty of mechanism — the AMPK/mTOR interplay has been mapped for over a decade — but rather the explicit linking of distinct fasting architectures to a unified pathway logic. That framing has practical utility: it suggests protocol choice matters less than achieving sufficient caloric deprivation duration to flip the AMPK-to-mTOR ratio. For adults navigating IF regimens, this implies a metabolic threshold model rather than a protocol-specific prescription.
However, this is a narrative review, not primary data, and the authors acknowledge methodological inconsistencies across source studies — including heterogeneous cohort sizes, short intervention durations, and limited long-term human trials on longevity endpoints. Animal-to-human translation of autophagy benefits remains incompletely validated. The practical caution: populations with diabetes, eating disorder history, or cardiovascular instability require supervised implementation. Incremental synthesis rather than paradigm-shifting, but useful clinical scaffolding.
